ClinicalTrials.gg
CompletedNCT01950364Updated May 11, 2016Results posted

A Phase 1 Study in Patients With Relapsed or Refractory Hodgkin Lymphoma or Systemic Anaplastic Large Cell Lymphoma

A Phase 1 interventional study of brentuximab vedotin and Brentuximab vedotin and rifampicin in Hodgkin Lymphoma and Anaplastic Large-cell Lymphoma, sponsored by Millennium Pharmaceuticals, Inc.. Completed at 6 sites in 3 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2016-05-11.

Sponsored by Millennium Pharmaceuticals, Inc. (part of Takeda) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
20
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 80 studies testing Brentuximab Vedotin in Hodgkin Disease — 14 open to participants now, 28 under way, 8 of them phase 3. Brentuximab Vedotin · Hodgkin Disease.

Enrollment
66th of 80
20 · median 52
Started
2013
with 9 others
Phase 1
12 of 80
none open now
Registered
26th of 80
by date
Lead sponsor
3 of 80
Millennium Pharmaceuticals, Inc.

Among the 80 studies testing Brentuximab Vedotin in Hodgkin Disease, this one is the 66th largest by enrollment, is one of 10 that started in 2013, is one of 12 in phase 1, and was the 26th registered.

Hodgkin Disease

1,383 studies on the registry are indexed under Hodgkin Disease; 163 are open to participants now.

Browse Hodgkin Disease studies →

Open to participants now

14 of the 80 studies testing Brentuximab Vedotin in Hodgkin Disease are open now, in 12 countries. Recruiting first, the newest first:

9 more — sign in →

By country, each count listing its studies:

All 14 open studies →

About Brentuximab Vedotin

Brentuximab Vedotin: first FDA approval 2011 (ADCETRIS), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 136 Hodgkin Disease studies recruiting now, 73 (54%) set no upper age limit and 51 (38%) stop at 75 or younger; 46 take children under 18; 10 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 80 studies testing Brentuximab Vedotin in Hodgkin Disease, or all of them as a file.
02

Study summary

This is an open-label trial to estimate the concentrations of brentuximab vedotin in relapsed/refractory Hodgkin lymphoma (HL) or relapsed/refractory systemic anaplastic large cell lymphoma (sALCL) participants treated with either brentuximab vedotin or brentuximab vedotin + rifampicin.

03

Conditions studied

  • Hodgkin Lymphoma
  • Anaplastic Large-cell Lymphoma

Keywords

  • Lymphoma
  • Hodgkin
  • Anaplastic Large-cell
  • Relapsed
  • Refractory
  • Antigens, CD30
  • Antibody-Drug Conjugate
  • Antibodies, Monoclonal
  • Lymphoma, Non-Hodgkin
  • Lymphoma, Large-Cell, Anaplastic
  • Monomethyl auristatin E
  • Drug Therapy
  • Immunotherapy
  • Hematologic Diseases
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female participants between 18 years and 75 years old, with HL or relapsed or refractory sALCL who have previously received at least 1 multiagent chemotherapy
  • An (ECOG) performance of 0 or 1
  • Female participants who are for at least 1 year before the screening visit, surgically sterile, or agree to practice 2 effective methods of , at the same time, from the time of signing the form through 30 days after the last dose of study drug, or agree to practice true abstinence
  • Male participants who agree to practice effective barrier contraception during the entire study treatment period through 6 months after the last dose of study drug or agree to practice true abstinence
  • Clinical laboratory values as specified in the study protocol

Exclusion criteria

Exclusion Criteria:

  • Participants for whom rifampicin is
  • Previously received an transplant.
  • Participants with current diagnosis of primary cutaneous anaplastic large cell lymphoma (ALCL) (participants whose ALCL has transformed to sALCL are eligible).
  • Known cerebral/meningeal disease including signs or symptoms of progressive multifocal leukoencephalopathy (PML)
  • Female participants who are lactating and breastfeeding or pregnant
  • Known (HIV) positive,
  • Known surface antigen-positive, or known or suspected active infection
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
20 participants (actual)

Study arms

  • Experimental
    Arm A: Brentuximab vedotin

    Brentuximab vedotin will be administered every 3 weeks at a dose of 1.8 mg/kg.

    Drug: brentuximab vedotin

  • Experimental
    Arm B: Brentuximab vedotin and rifampicin

    Brentuximab vedotin will be administered every 3 weeks at a dose of 1.8 mg/kg beginning on Cycle 1, Day 1; daily rifampicin (600 mg PO) will be administered during Cycles 0 through 3 only, beginning on Cycle 0, Day 1 (7 days before the Cycle 1, Day 1 dose of brentuximab vedotin) and continuing through Cycle 3, Day 21.

    Drug: Brentuximab vedotin and rifampicin

Interventions

  • Brentuximab vedotin will be administered every 3 weeks at a dose of 1.8 mg/kg.

    Also known as: SGN-35

  • DrugBrentuximab vedotin and rifampicin

    Drug pages: Brentuximab Vedotin · Rifampin

    Brentuximab vedotin will be administered every 3 weeks at a dose of 1.8 mg/kg beginning on Cycle 1, Day 1; daily rifampicin (600 mg PO) will be administered during Cycles 0 through 3 only, beginning on Cycle 0, Day 1 (7 days before the Cycle 1, Day 1 dose of brentuximab vedotin) and continuing through Cycle 3, Day 21.

    Also known as: SGN-35

06

What researchers measure

Primary outcomes

  1. Plasma Concentration of Monomethylauristatin E (MMAE) and Its Metabolites at Cycle 1, Predose

    Metabolites of MMAE includes C4, C5, C7, C8 and C13. The lower limit of Quantification (LLQ) for all the observations was 0.01 nanogram/milliliter (ng/mL).

    Time frame: Cycle 1: Predose

  2. Plasma Concentration of Monomethylauristatin E (MMAE) and Its Metabolites at Cycle 2, Predose

    Metabolites of MMAE includes C4, C5, C7, C8 and C13. The LLQ for all the observations was 0.01 ng/mL.

    Time frame: Cycle 2: Predose

  3. Plasma Concentration of Monomethylauristatin E (MMAE) and Its Metabolites at Cycle 3, Predose

    Metabolites of MMAE includes C4, C5, C7, C8 and C13. The LLQ for all the observations was 0.01 ng/mL.

    Time frame: Cycle 3: Predose

  4. Plasma Concentration of Monomethylauristatin E (MMAE) and Its Metabolites at Cycle 1, 0.5 Hour Postdose

    Metabolites of MMAE includes C4, C5, C7, C8 and C13. The LLQ for all the observations was 0.01 ng/mL.

    Time frame: Cycle 1: 0.5 hour postdose

  5. Plasma Concentration of Monomethylauristatin E (MMAE) and Its Metabolites at Cycle 2, 0.5 Hour Postdose

    Metabolites of MMAE includes C4, C5, C7, C8 and C13. The LLQ for all the observations was 0.01 ng/mL.

    Time frame: Cycle 2: 0.5 hour postdose

  6. Plasma Concentration of Monomethylauristatin E (MMAE) and Its Metabolites at Cycle 3, 0.5 Hour Postdose

    Metabolites of MMAE includes C4, C5, C7, C8 and C13. The LLQ for all the observations was 0.01 ng/mL.

    Time frame: Cycle 3: 0.5 hour postdose

  7. Plasma Concentration of Monomethylauristatin E (MMAE) and Its Metabolites at Cycle 1, 4 Hour Postdose

    Metabolites of MMAE includes C4, C5, C7, C8 and C13. The LLQ for all the observations was 0.01 ng/mL.

    Time frame: Cycle 1: 4 hour postdose

  8. Plasma Concentration of Monomethylauristatin E (MMAE) and Its Metabolites at Cycle 3, 4 Hour Postdose

    Metabolites of MMAE includes C4, C5, C7, C8 and C13. The LLQ for all the observations was 0.01 ng/mL.

    Time frame: Cycle 3: 4 hour postdose

  9. Plasma Concentration of Monomethylauristatin E (MMAE) and Its Metabolites at Cycle 1, 24 Hour Postdose

    Metabolites of MMAE includes C4, C5, C7, C8 and C13. The LLQ for all the observations was 0.01 ng/mL.

    Time frame: Cycle 1: 24 hour postdose

  10. Plasma Concentration of Monomethylauristatin E (MMAE) and Its Metabolites at Cycle 3, 24 Hour Postdose

    Metabolites of MMAE includes C4, C5, C7, C8 and C13. The LLQ for all the observations was 0.01 ng/mL.

    Time frame: Cycle 3: 24 hour postdose

  11. Plasma Concentration of Monomethylauristatin E (MMAE) and Its Metabolites at Cycle 1, 48 Hour Postdose

    Metabolites of MMAE includes C4, C5, C7, C8 and C13. The LLQ for all the observations was 0.01 ng/mL.

    Time frame: Cycle 1: 48 hour postdose

  12. Plasma Concentration of Monomethylauristatin E (MMAE) and Its Metabolites at Cycle 3, 48 Hour Postdose

    Metabolites of MMAE includes C4, C5, C7, C8 and C13. The LLQ for all the observations was 0.01 ng/mL.

    Time frame: Cycle 3: 48 hour postdose

  13. Plasma Concentration of Monomethylauristatin E (MMAE) and Its Metabolites at Cycle 1, 72 Hour Postdose

    Metabolites of MMAE includes C4, C5, C7, C8 and C13. The LLQ for all the observations was 0.01 ng/mL.

    Time frame: Cycle 1: 72 hour postdose

  14. Plasma Concentration of Monomethylauristatin E (MMAE) and Its Metabolites at Cycle 3, 72 Hour Postdose

    Metabolites of MMAE includes C4, C5, C7, C8 and C13. The LLQ for all the observations was 0.01 ng/mL.

    Time frame: Cycle 3: 72 hour postdose

  15. Plasma Concentration of Monomethylauristatin E (MMAE) and Its Metabolites at Cycle 1, 96 Hour Postdose

    Metabolites of MMAE includes C4, C5, C7, C8 and C13. The LLQ for all the observations was 0.01 ng/mL.

    Time frame: Cycle 1: 96 hour postdose

  16. Plasma Concentration of Monomethylauristatin E (MMAE) and Its Metabolites at Cycle 3, 96 Hour Postdose

    Metabolites of MMAE includes C4, C5, C7, C8 and C13. The LLQ for all the observations was 0.01 ng/mL.

    Time frame: Cycle 3: 96 hour postdose

  17. Plasma Concentration of Monomethylauristatin E (MMAE) and Its Metabolites at Cycle 1, 144 Hour Postdose

    Metabolites of MMAE includes C4, C5, C7, C8 and C13. The LLQ for all the observations was 0.01 ng/mL.

    Time frame: Cycle 1: 144 hour postdose

  18. Plasma Concentration of Monomethylauristatin E (MMAE) and Its Metabolites at Cycle 3, 144 Hour Postdose

    Metabolites of MMAE includes C4, C5, C7, C8 and C13. The LLQ for all the observations was 0.01 ng/mL.

    Time frame: Cycle 3: 144 hour postdose

  19. Plasma Concentration of Monomethylauristatin E (MMAE) and Its Metabolites at Cycle 1, 336 Hour Postdose

    Metabolites of MMAE includes C4, C5, C7, C8 and C13. The LLQ for all the observations was 0.01 ng/mL.

    Time frame: Cycle 1: 336 hour postdose

  20. Plasma Concentration of Monomethylauristatin E (MMAE) and Its Metabolites at Cycle 3, 336 Hour Postdose

    Metabolites of MMAE includes C4, C5, C7, C8 and C13. The LLQ for all the observations was 0.01 ng/mL.

    Time frame: Cycle 3: 336 hour postdose

  21. Plasma Concentration of Monomethylauristatin E (MMAE) and Its Metabolites at Cycle 3, 480 Hour Postdose

    Metabolites of MMAE includes C4, C5, C7, C8 and C13. The LLQ for all the observations was 0.01 ng/mL.

    Time frame: Cycle 3: 480 hour postdose

  22. Amount of Monomethylauristatin E (MMAE) and Its Metabolites Excreted in Urine at Cycle 1, Predose

    Metabolites of MMAE includes C4, C5, C7, C8 and C13. Amount of MMAE and its metabolites in urine were determined by multiplying the volume of urine obtained and the concentration of MMAE and its metabolites present in it, respectively. The LLQ for determining the concentration was 0.01 ng/mL.

    Time frame: Cycle 1: Predose

  23. Amount of Monomethylauristatin E (MMAE) and Its Metabolites Excreted in Urine at Cycle 1, 0-24 Hours Postdose

    Metabolites of MMAE includes C4, C5, C7, C8 and C13. Amount of MMAE and its metabolites in urine were determined by multiplying the volume of urine obtained and the concentration of MMAE and its metabolites present in it, respectively. The LLQ for determining the concentration was 0.01 ng/mL.

    Time frame: Cycle 1: 0-24 hours postdose

  24. Amount of Monomethylauristatin E (MMAE) and Its Metabolites Excreted in Urine at Cycle 1, 24-48 Hours Postdose

    Metabolites of MMAE includes C4, C5, C7, C8 and C13. Amount of MMAE and its metabolites in urine were determined by multiplying the volume of urine obtained and the concentration of MMAE and its metabolites present in it, respectively. The LLQ for determining the concentration was 0.01 ng/mL.

    Time frame: Cycle 1: 24-48 hours postdose

  25. Amount of Monomethylauristatin E (MMAE) and Its Metabolites Excreted in Urine at Cycle 1, 48-72 Hours Postdose

    Metabolites of MMAE includes C4, C5, C7, C8 and C13. Amount of MMAE and its metabolites in urine were determined by multiplying the volume of urine obtained and the concentration of MMAE and its metabolites present in it, respectively. The LLQ for determining the concentration was 0.01 ng/mL.

    Time frame: Cycle 1: 48-72 hours postdose

  26. Amount of Monomethylauristatin E (MMAE) and Its Metabolites Excreted in Urine at Cycle 1, 72-96 Hours Postdose

    Metabolites of MMAE includes C4, C5, C7, C8 and C13. Amount of MMAE and its metabolites in urine were determined by multiplying the volume of urine obtained and the concentration of MMAE and its metabolites present in it, respectively. The LLQ for determining the concentration was 0.01 ng/mL.

    Time frame: Cycle 1: 72-96 hours postdose

  27. Amount of Monomethylauristatin E (MMAE) and Its Metabolites Excreted in Urine at Cycle 1, 96-120 Hours Postdose

    Metabolites of MMAE includes C4, C5, C7, C8 and C13. Amount of MMAE and its metabolites in urine were determined by multiplying the volume of urine obtained and the concentration of MMAE and its metabolites present in it, respectively. The LLQ for determining the concentration was 0.01 ng/mL.

    Time frame: Cycle 1: 96-120 hours postdose

  28. Amount of Monomethylauristatin E (MMAE) and Its Metabolites Excreted in Urine at Cycle 1, 120-144 Hours Postdose

    Metabolites of MMAE includes C4, C5, C7, C8 and C13. Amount of MMAE and its metabolites in urine were determined by multiplying the volume of urine obtained and the concentration of MMAE and its metabolites present in it, respectively. The LLQ for determining the concentration was 0.01 ng/mL.

    Time frame: Cycle 1: 120-144 hours postdose

  29. Amount of Monomethylauristatin E (MMAE) and Its Metabolites Excreted in Urine at Cycle 1, 144-168 Hours Postdose

    Metabolites of MMAE includes C4, C5, C7, C8 and C13. Amount of MMAE and its metabolites in urine were determined by multiplying the volume of urine obtained and the concentration of MMAE and its metabolites present in it, respectively. The LLQ for determining the concentration was 0.01 ng/mL.

    Time frame: Cycle 1: 144-168 hours postdose

  30. Amount of Monomethylauristatin E (MMAE) and Its Metabolites Excreted in Urine at Cycle 1, 336-360 Hours Postdose

    Metabolites of MMAE includes C4, C5, C7, C8 and C13. Amount of MMAE and its metabolites in urine were determined by multiplying the volume of urine obtained and the concentration of MMAE and its metabolites present in it, respectively. The LLQ for determining the concentration was 0.01 ng/mL.

    Time frame: Cycle 1: 336-360 hours postdose

  31. Amount of Monomethylauristatin E (MMAE) and Its Metabolites Excreted in Urine at Cycle 1, 480-504 Hours Postdose

    Metabolites of MMAE includes C4, C5, C7, C8 and C13. Amount of MMAE and its metabolites in urine were determined by multiplying the volume of urine obtained and the concentration of MMAE and its metabolites present in it, respectively. The LLQ for determining the concentration was 0.01 ng/mL.

    Time frame: Cycle 1: 480-504 hours postdose

  32. Amount of Monomethylauristatin E (MMAE) and Its Metabolites Excreted in Urine at Cycle 3, Predose

    Metabolites of MMAE includes C4, C5, C7, C8 and C13. Amount of MMAE and its metabolites in urine were determined by multiplying the volume of urine obtained and the concentration of MMAE and its metabolites present in it, respectively. The LLQ for determining the concentration was 0.01 ng/mL.

    Time frame: Cycle 3: Predose

  33. Amount of Monomethylauristatin E (MMAE) and Its Metabolites Excreted in Urine at Cycle 3, 0-24 Hours Postdose

    Metabolites of MMAE includes C4, C5, C7, C8 and C13. Amount of MMAE and its metabolites in urine were determined by multiplying the volume of urine obtained and the concentration of MMAE and its metabolites present in it, respectively. The LLQ for determining the concentration was 0.01 ng/mL.

    Time frame: Cycle 3: 0-24 hours postdose

  34. Amount of Monomethylauristatin E (MMAE) and Its Metabolites Excreted in Urine at Cycle 3, 24-48 Hours Postdose

    Metabolites of MMAE includes C4, C5, C7, C8 and C13. Amount of MMAE and its metabolites in urine were determined by multiplying the volume of urine obtained and the concentration of MMAE and its metabolites present in it, respectively. The LLQ for determining the concentration was 0.01 ng/mL.

    Time frame: Cycle 3: 24-48 hours postdose

  35. Amount of Monomethylauristatin E (MMAE) and Its Metabolites Excreted in Urine at Cycle 3, 48-72 Hours Postdose

    Metabolites of MMAE includes C4, C5, C7, C8 and C13. Amount of MMAE and its metabolites in urine were determined by multiplying the volume of urine obtained and the concentration of MMAE and its metabolites present in it, respectively. The LLQ for determining the concentration was 0.01 ng/mL.

    Time frame: Cycle 3: 48-72 hours postdose

  36. Amount of Monomethylauristatin E (MMAE) and Its Metabolites Excreted in Urine at Cycle 3, 72-96 Hours Postdose

    Metabolites of MMAE includes C4, C5, C7, C8 and C13. Amount of MMAE and its metabolites in urine were determined by multiplying the volume of urine obtained and the concentration of MMAE and its metabolites present in it, respectively. The LLQ for determining the concentration was 0.01 ng/mL.

    Time frame: Cycle 3: 72-96 hours postdose

  37. Amount of Monomethylauristatin E (MMAE) and Its Metabolites Excreted in Urine at Cycle 3, 96-120 Hours Postdose

    Metabolites of MMAE includes C4, C5, C7, C8 and C13. Amount of MMAE and its metabolites in urine were determined by multiplying the volume of urine obtained and the concentration of MMAE and its metabolites present in it, respectively. The LLQ for determining the concentration was 0.01 ng/mL.

    Time frame: Cycle 3: 96-120 hours postdose

  38. Amount of Monomethylauristatin E (MMAE) and Its Metabolites Excreted in Urine at Cycle 3, 120-144 Hours Postdose

    Metabolites of MMAE includes C4, C5, C7, C8 and C13. Amount of MMAE and its metabolites in urine were determined by multiplying the volume of urine obtained and the concentration of MMAE and its metabolites present in it, respectively. The LLQ for determining the concentration was 0.01 ng/mL.

    Time frame: Cycle 3: 120-144 hours postdose

  39. Amount of Monomethylauristatin E (MMAE) and Its Metabolites Excreted in Urine at Cycle 3, 144-168 Hours Postdose

    Metabolites of MMAE includes C4, C5, C7, C8 and C13. Amount of MMAE and its metabolites in urine were determined by multiplying the volume of urine obtained and the concentration of MMAE and its metabolites present in it, respectively. The LLQ for determining the concentration was 0.01 ng/mL.

    Time frame: Cycle 3: 144-168 hours postdose

  40. Amount of Monomethylauristatin E (MMAE) and Its Metabolites Excreted in Urine at Cycle 3, 336-360 Hours Postdose

    Metabolites of MMAE includes C4, C5, C7, C8 and C13. Amount of MMAE and its metabolites in urine were determined by multiplying the volume of urine obtained and the concentration of MMAE and its metabolites present in it, respectively. The LLQ for determining the concentration was 0.01 ng/mL.

    Time frame: Cycle 3: 336-360 hours postdose

  41. Amount of Monomethylauristatin E (MMAE) and Its Metabolites Excreted in Urine at Cycle 3, 480-504 Hours Postdose

    Metabolites of MMAE includes C4, C5, C7, C8 and C13. Amount of MMAE and its metabolites in urine were determined by multiplying the volume of urine obtained and the concentration of MMAE and its metabolites present in it, respectively. The LLQ for determining the concentration was 0.01 ng/mL.

    Time frame: Cycle 3: 480-504 hours postdose

Secondary outcomes

  1. Serum Concentrations of Antibody-drug Conjugate (ADC)

    The LLQ for all the observations was 12.5 ng/mL.

    Time frame: Cycle 1 and 3: Predose, 0.5, 4, 72, 336 hours post-dose; Cycle 2: Predose, 0.5 hours post-dose; Cycle 3: 480 hours post-dose

  2. Serum Concentration of Total Antibody (TAb)

    The LLQ for all the observations was 12.5 ng/mL.

    Time frame: Cycle 1 and 3: Predose, 0.5, 4, 72, 336 hours post-dose; Cycle 2: Predose, 0.5 hours post-dose; Cycle 3: 480 hours post-dose

  3. Number of Participants Reporting One or More Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)

    An Adverse Event (AE) is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (example, a clinically significant abnormal laboratory finding), symptom, or disease temporally associated with the use of a drug, whether or not it is considered related to the drug. A treatment-emergent adverse event (TEAE) is defined as an adverse event with an onset that occurs after receiving study drug. A serious adverse event (SAE) is an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; or congenital anomaly; or a medically important event. AEs included both SAE and non-SAE.

    Time frame: Baseline up to 30 days after last dose of study drug (30 days after Cycle 16)

  4. Number of Participants With Anti-therapeutic Antibodies (ATA) to Brentuximab Vedotin

    Participants with positive ATA at both Cycle 1 and 3, negative ATA at both Cycle 1 and 3, and transient positive (positive at one time point, but negative at the other) ATA for brentuximab vedotin were reported.

    Time frame: Day 1 of Cycle 1 and 3

  5. Number of Participants With Markedly Abnormal Laboratory Values

    The number of participants with any markedly abnormal standard safety laboratory values collected throughout study.

    Time frame: Baseline up to 30 days after last dose of study drug (30 Days after Cycle 16)

  6. Number of Participants With Clinically Significant Change From Baseline in Vital Signs

    Vital signs included body temperature, body weight, blood pressure and heart rate.

    Time frame: Baseline up to 30 days after last dose of study drug (30 Days after Cycle 16)

07

Results

Posted Feb 9, 2016

Participant flow

Participants took part in the study at 5 investigative sites in Belgium, Lithuania and Spain from 27 November 2013 to 16 June 2015.

Participant flow — Overall Study
MilestoneBrentuximab VedotinBrentuximab Vedotin + Rifampicin
Started1010
Completed00
Not completed1010
Withdrew: Adverse event30
Withdrew: Stem cell transplant26
Withdrew: Disease progression52
Withdrew: Withdrawal by subject01
Withdrew: Protocol violation01

Outcome measures

PrimaryPlasma Concentration of Monomethylauristatin E (MMAE) and Its Metabolites at Cycle 1, Predose

Metabolites of MMAE includes C4, C5, C7, C8 and C13. The lower limit of Quantification (LLQ) for all the observations was 0.01 nanogram/milliliter (ng/mL).

Time frame:
Cycle 1: Predose
Reported as:
Geometric mean · ng/mL
Plasma Concentration of Monomethylauristatin E (MMAE) and Its Metabolites at Cycle 1, Predose
ng/mLBrentuximab VedotinBrentuximab Vedotin + Rifampicin
MMAENA ± NANA ± NA
C4NA ± NANA ± NA
C5NA ± NANA ± NA
C7NA ± NANA ± NA
C8NA ± NANA ± NA
C13NA ± NANA ± NA
SecondarySerum Concentrations of Antibody-drug Conjugate (ADC)

The LLQ for all the observations was 12.5 ng/mL.

Time frame:
Cycle 1 and 3: Predose, 0.5, 4, 72, 336 hours post-dose; Cycle 2: Predose, 0.5 hours post-dose; Cycle 3: 480 hours post-dose
Reported as:
Geometric mean · ng/mL
Serum Concentrations of Antibody-drug Conjugate (ADC)
ng/mLBrentuximab VedotinBrentuximab Vedotin + Rifampicin
Cycle 1, PredoseNA ± NANA ± NA
Cycle 1, 0.5 hour29609.7759 ± 11865.3570233125.0025 ± 10398.79403
Cycle 1, 4 hour24398.6482 ± 8092.4144824533.2372 ± 6767.70744
Cycle 1, 72 hour4265.7542 ± 2880.396605958.0569 ± 1788.56378
Cycle 1, 336 hour1167.0713 ± 740.056501108.6515 ± 376.81123
Cycle 2, Predose794.3851 ± 10732.46886435.1550 ± 303.25245
Cycle 2, 0.5 hour16032.6494 ± 15714.5982131627.2566 ± 6716.71906
Cycle 3, Predose611.0573 ± 786.52082536.3692 ± 524.72923
Cycle 3, 0.5 hour20991.9618 ± 12662.0508733040.2245 ± 6295.45517
Cycle 3, 4 hour15378.8274 ± 9550.9990324496.7203 ± 4212.84997
Cycle 3, 72 hour3258.7237 ± 3358.785044262.0364 ± 2431.24647
Cycle 3, 336 hour1381.2290 ± 1224.668571363.9488 ± 789.04877
Cycle 3, 480 hour648.2492 ± 1065.26404734.5557 ± 634.23889
SecondarySerum Concentration of Total Antibody (TAb)

The LLQ for all the observations was 12.5 ng/mL.

Time frame:
Cycle 1 and 3: Predose, 0.5, 4, 72, 336 hours post-dose; Cycle 2: Predose, 0.5 hours post-dose; Cycle 3: 480 hours post-dose
Reported as:
Geometric mean · ng/mL
Serum Concentration of Total Antibody (TAb)
ng/mLBrentuximab VedotinBrentuximab Vedotin + Rifampicin
Cycle 1, PredoseNA ± NANA ± NA
Cycle 1, 0.5 hour30874.4957 ± 11904.1849430884.9074 ± 9956.67036
Cycle 1, 4 hour28577.3869 ± 9365.8874628865.4674 ± 8192.50406
Cycle 1, 72 hour9931.2943 ± 4973.7469211626.2147 ± 4396.55604
Cycle 1, 336 hour2898.2924 ± 1831.739973066.5859 ± 1017.84204
Cycle 2, Predose2055.3871 ± 10312.912801363.8319 ± 904.27346
Cycle 2, 0.5 hour17378.2105 ± 17543.5196831583.7793 ± 7742.69918
Cycle 3, Predose1361.3147 ± 1592.899931517.6506 ± 1200.68646
Cycle 3, 0.5 hour15974.3723 ± 12467.1036833892.4731 ± 10595.70675
Cycle 3, 4 hour11609.1430 ± 14719.6996827548.1773 ± 7219.71925
Cycle 3, 72 hour13594.2016 ± 7492.707429588.9374 ± 5665.38218
Cycle 3, 336 hour3206.6925 ± 3000.221163628.9175 ± 1802.66091
Cycle 3, 480 hour1329.0886 ± 2024.172131866.5746 ± 1326.12113
PrimaryPlasma Concentration of Monomethylauristatin E (MMAE) and Its Metabolites at Cycle 2, Predose

Metabolites of MMAE includes C4, C5, C7, C8 and C13. The LLQ for all the observations was 0.01 ng/mL.

Time frame:
Cycle 2: Predose
Reported as:
Geometric mean · ng/mL
Plasma Concentration of Monomethylauristatin E (MMAE) and Its Metabolites at Cycle 2, Predose
ng/mLBrentuximab VedotinBrentuximab Vedotin + Rifampicin
MMAE0.0919 ± 0.056950.0795 ± 0.14220
C4NA ± NANA ± NA
C5NA ± NANA ± NA
C7NA ± NANA ± NA
C8NA ± NANA ± NA
C13NA ± NANA ± NA
PrimaryPlasma Concentration of Monomethylauristatin E (MMAE) and Its Metabolites at Cycle 3, Predose

Metabolites of MMAE includes C4, C5, C7, C8 and C13. The LLQ for all the observations was 0.01 ng/mL.

Time frame:
Cycle 3: Predose
Reported as:
Geometric mean · ng/mL
Plasma Concentration of Monomethylauristatin E (MMAE) and Its Metabolites at Cycle 3, Predose
ng/mLBrentuximab VedotinBrentuximab Vedotin + Rifampicin
MMAE0.1046 ± 0.108400.0727 ± 0.05936
C4NA ± NANA ± NA
C5NA ± NANA ± NA
C7NA ± NANA ± NA
C8NA ± NANA ± NA
C13NA ± NANA ± NA
PrimaryPlasma Concentration of Monomethylauristatin E (MMAE) and Its Metabolites at Cycle 1, 0.5 Hour Postdose

Metabolites of MMAE includes C4, C5, C7, C8 and C13. The LLQ for all the observations was 0.01 ng/mL.

Time frame:
Cycle 1: 0.5 hour postdose
Reported as:
Geometric mean · ng/mL
Plasma Concentration of Monomethylauristatin E (MMAE) and Its Metabolites at Cycle 1, 0.5 Hour Postdose
ng/mLBrentuximab VedotinBrentuximab Vedotin + Rifampicin
MMAE0.3902 ± 1.336350.2149 ± 0.43900
C40.0184 ± 0.00613NA ± NA
C5NA ± NANA ± NA
C7NA ± NANA ± NA
C80.0267 ± 0.02119NA ± NA
C130.0108 ± 0.00360NA ± NA
PrimaryPlasma Concentration of Monomethylauristatin E (MMAE) and Its Metabolites at Cycle 2, 0.5 Hour Postdose

Metabolites of MMAE includes C4, C5, C7, C8 and C13. The LLQ for all the observations was 0.01 ng/mL.

Time frame:
Cycle 2: 0.5 hour postdose
Reported as:
Geometric mean · ng/mL
Plasma Concentration of Monomethylauristatin E (MMAE) and Its Metabolites at Cycle 2, 0.5 Hour Postdose
ng/mLBrentuximab VedotinBrentuximab Vedotin + Rifampicin
MMAE0.3119 ± 1.692490.2929 ± 1.39185
C4NA ± NANA ± NA
C5NA ± NANA ± NA
C7NA ± NANA ± NA
C8NA ± NA0.0228 ± 0.00760
C13NA ± NANA ± NA
PrimaryPlasma Concentration of Monomethylauristatin E (MMAE) and Its Metabolites at Cycle 3, 0.5 Hour Postdose

Metabolites of MMAE includes C4, C5, C7, C8 and C13. The LLQ for all the observations was 0.01 ng/mL.

Time frame:
Cycle 3: 0.5 hour postdose
Reported as:
Geometric mean · ng/mL
Plasma Concentration of Monomethylauristatin E (MMAE) and Its Metabolites at Cycle 3, 0.5 Hour Postdose
ng/mLBrentuximab VedotinBrentuximab Vedotin + Rifampicin
MMAE0.3307 ± 2.335390.2577 ± 0.26736
C40.0256 ± 0.00905NA ± NA
C5NA ± NANA ± NA
C7NA ± NANA ± NA
C80.0323 ± 0.03266NA ± NA
C130.0210 ± 0.00742NA ± NA
PrimaryPlasma Concentration of Monomethylauristatin E (MMAE) and Its Metabolites at Cycle 1, 4 Hour Postdose

Metabolites of MMAE includes C4, C5, C7, C8 and C13. The LLQ for all the observations was 0.01 ng/mL.

Time frame:
Cycle 1: 4 hour postdose
Reported as:
Geometric mean · ng/mL
Plasma Concentration of Monomethylauristatin E (MMAE) and Its Metabolites at Cycle 1, 4 Hour Postdose
ng/mLBrentuximab VedotinBrentuximab Vedotin + Rifampicin
MMAE2.2778 ± 4.420891.7836 ± 0.93129
C40.0547 ± 0.02737NA ± NA
C50.0254 ± 0.01326NA ± NA
C70.0195 ± 0.01293NA ± NA
C80.0557 ± 0.056310.0160 ± 0.00921
C130.0151 ± 0.00752NA ± NA
PrimaryPlasma Concentration of Monomethylauristatin E (MMAE) and Its Metabolites at Cycle 3, 4 Hour Postdose

Metabolites of MMAE includes C4, C5, C7, C8 and C13. The LLQ for all the observations was 0.01 ng/mL.

Time frame:
Cycle 3: 4 hour postdose
Reported as:
Geometric mean · ng/mL
Plasma Concentration of Monomethylauristatin E (MMAE) and Its Metabolites at Cycle 3, 4 Hour Postdose
ng/mLBrentuximab VedotinBrentuximab Vedotin + Rifampicin
MMAE1.7171 ± 4.429141.4529 ± 1.36620
C40.0397 ± 0.01323NA ± NA
C50.0163 ± 0.00804NA ± NA
C70.0118 ± 0.00600NA ± NA
C80.0446 ± 0.050110.0190 ± 0.01265
C130.0191 ± 0.00637NA ± NA
PrimaryPlasma Concentration of Monomethylauristatin E (MMAE) and Its Metabolites at Cycle 1, 24 Hour Postdose

Metabolites of MMAE includes C4, C5, C7, C8 and C13. The LLQ for all the observations was 0.01 ng/mL.

Time frame:
Cycle 1: 24 hour postdose
Reported as:
Geometric mean · ng/mL
Plasma Concentration of Monomethylauristatin E (MMAE) and Its Metabolites at Cycle 1, 24 Hour Postdose
ng/mLBrentuximab VedotinBrentuximab Vedotin + Rifampicin
MMAE3.7950 ± 4.124463.1227 ± 2.38909
C40.0443 ± 0.053280.0191 ± 0.00637
C50.0218 ± 0.02814NA ± NA
C70.0206 ± 0.01477NA ± NA
C80.0805 ± 0.069860.0196 ± 0.01702
C130.0142 ± 0.006600.0113 ± 0.00377
PrimaryPlasma Concentration of Monomethylauristatin E (MMAE) and Its Metabolites at Cycle 3, 24 Hour Postdose

Metabolites of MMAE includes C4, C5, C7, C8 and C13. The LLQ for all the observations was 0.01 ng/mL.

Time frame:
Cycle 3: 24 hour postdose
Reported as:
Geometric mean · ng/mL
Plasma Concentration of Monomethylauristatin E (MMAE) and Its Metabolites at Cycle 3, 24 Hour Postdose
ng/mLBrentuximab VedotinBrentuximab Vedotin + Rifampicin
MMAE3.2336 ± 2.263692.2558 ± 1.60345
C40.0200 ± 0.01071NA ± NA
C50.0203 ± 0.01109NA ± NA
C70.0164 ± 0.00868NA ± NA
C80.0715 ± 0.045230.0177 ± 0.01284
C130.0105 ± 0.00371NA ± NA
PrimaryPlasma Concentration of Monomethylauristatin E (MMAE) and Its Metabolites at Cycle 1, 48 Hour Postdose

Metabolites of MMAE includes C4, C5, C7, C8 and C13. The LLQ for all the observations was 0.01 ng/mL.

Time frame:
Cycle 1: 48 hour postdose
Reported as:
Geometric mean · ng/mL
Plasma Concentration of Monomethylauristatin E (MMAE) and Its Metabolites at Cycle 1, 48 Hour Postdose
ng/mLBrentuximab VedotinBrentuximab Vedotin + Rifampicin
MMAE4.2140 ± 3.694703.3727 ± 2.61792
C40.0424 ± 0.052590.0128 ± 0.00565
C50.0168 ± 0.02553NA ± NA
C70.0187 ± 0.01608NA ± NA
C80.0959 ± 0.067800.0210 ± 0.01455
C130.0134 ± 0.00763NA ± NA
PrimaryPlasma Concentration of Monomethylauristatin E (MMAE) and Its Metabolites at Cycle 3, 48 Hour Postdose

Metabolites of MMAE includes C4, C5, C7, C8 and C13. The LLQ for all the observations was 0.01 ng/mL.

Time frame:
Cycle 3: 48 hour postdose
Reported as:
Geometric mean · ng/mL
Plasma Concentration of Monomethylauristatin E (MMAE) and Its Metabolites at Cycle 3, 48 Hour Postdose
ng/mLBrentuximab VedotinBrentuximab Vedotin + Rifampicin
MMAE3.4733 ± 2.177922.2156 ± 1.70890
C40.0193 ± 0.01407NA ± NA
C50.0198 ± 0.01316NA ± NA
C70.0170 ± 0.01112NA ± NA
C80.0746 ± 0.061620.0195 ± 0.01114
C130.0124 ± 0.00438NA ± NA
PrimaryPlasma Concentration of Monomethylauristatin E (MMAE) and Its Metabolites at Cycle 1, 72 Hour Postdose

Metabolites of MMAE includes C4, C5, C7, C8 and C13. The LLQ for all the observations was 0.01 ng/mL.

Time frame:
Cycle 1: 72 hour postdose
Reported as:
Geometric mean · ng/mL
Plasma Concentration of Monomethylauristatin E (MMAE) and Its Metabolites at Cycle 1, 72 Hour Postdose
ng/mLBrentuximab VedotinBrentuximab Vedotin + Rifampicin
MMAE3.8931 ± 3.618343.0948 ± 2.03516
C40.0501 ± 0.062420.0127 ± 0.00423
C50.0190 ± 0.02664NA ± NA
C70.0241 ± 0.01640NA ± NA
C80.0899 ± 0.066880.0187 ± 0.01111
C130.0133 ± 0.00644NA ± NA
PrimaryPlasma Concentration of Monomethylauristatin E (MMAE) and Its Metabolites at Cycle 3, 72 Hour Postdose

Metabolites of MMAE includes C4, C5, C7, C8 and C13. The LLQ for all the observations was 0.01 ng/mL.

Time frame:
Cycle 3: 72 hour postdose
Reported as:
Geometric mean · ng/mL
Plasma Concentration of Monomethylauristatin E (MMAE) and Its Metabolites at Cycle 3, 72 Hour Postdose
ng/mLBrentuximab VedotinBrentuximab Vedotin + Rifampicin
MMAE3.3047 ± 2.141271.9732 ± 1.32391
C40.0310 ± 0.01563NA ± NA
C50.0256 ± 0.01510NA ± NA
C70.0168 ± 0.01126NA ± NA
C80.0728 ± 0.043480.0187 ± 0.01079
C13NA ± NANA ± NA
PrimaryPlasma Concentration of Monomethylauristatin E (MMAE) and Its Metabolites at Cycle 1, 96 Hour Postdose

Metabolites of MMAE includes C4, C5, C7, C8 and C13. The LLQ for all the observations was 0.01 ng/mL.

Time frame:
Cycle 1: 96 hour postdose
Reported as:
Geometric mean · ng/mL
Plasma Concentration of Monomethylauristatin E (MMAE) and Its Metabolites at Cycle 1, 96 Hour Postdose
ng/mLBrentuximab VedotinBrentuximab Vedotin + Rifampicin
MMAE2.9148 ± 1.705003.2956 ± 2.97022
C40.0136 ± 0.004810.1420 ± 0.04733
C50.0120 ± 0.006430.0593 ± 0.01977
C7NA ± NA0.0374 ± 0.01247
C80.0660 ± 0.043490.0228 ± 0.06198
C13NA ± NA0.0108 ± 0.00360
PrimaryPlasma Concentration of Monomethylauristatin E (MMAE) and Its Metabolites at Cycle 3, 96 Hour Postdose

Metabolites of MMAE includes C4, C5, C7, C8 and C13. The LLQ for all the observations was 0.01 ng/mL.

Time frame:
Cycle 3: 96 hour postdose
Reported as:
Geometric mean · ng/mL
Plasma Concentration of Monomethylauristatin E (MMAE) and Its Metabolites at Cycle 3, 96 Hour Postdose
ng/mLBrentuximab VedotinBrentuximab Vedotin + Rifampicin
MMAE2.4449 ± 1.443342.2344 ± 1.81211
C40.0140 ± 0.007040.0418 ± 0.01393
C50.0205 ± 0.010170.0294 ± 0.00980
C70.0121 ± 0.004280.0252 ± 0.00840
C80.0622 ± 0.043280.0392 ± 0.04163
C130.0105 ± 0.00371NA ± NA
PrimaryPlasma Concentration of Monomethylauristatin E (MMAE) and Its Metabolites at Cycle 1, 144 Hour Postdose

Metabolites of MMAE includes C4, C5, C7, C8 and C13. The LLQ for all the observations was 0.01 ng/mL.

Time frame:
Cycle 1: 144 hour postdose
Reported as:
Geometric mean · ng/mL
Plasma Concentration of Monomethylauristatin E (MMAE) and Its Metabolites at Cycle 1, 144 Hour Postdose
ng/mLBrentuximab VedotinBrentuximab Vedotin + Rifampicin
MMAE2.3326 ± 1.456191.7990 ± 0.89695
C40.0297 ± 0.02569NA ± NA
C50.0174 ± 0.01006NA ± NA
C70.0196 ± 0.00693NA ± NA
C80.0497 ± 0.027220.0120 ± 0.00542
C13NA ± NANA ± NA
PrimaryPlasma Concentration of Monomethylauristatin E (MMAE) and Its Metabolites at Cycle 3, 144 Hour Postdose

Metabolites of MMAE includes C4, C5, C7, C8 and C13. The LLQ for all the observations was 0.01 ng/mL.

Time frame:
Cycle 3: 144 hour postdose
Reported as:
Geometric mean · ng/mL
Plasma Concentration of Monomethylauristatin E (MMAE) and Its Metabolites at Cycle 3, 144 Hour Postdose
ng/mLBrentuximab VedotinBrentuximab Vedotin + Rifampicin
MMAE2.0555 ± 1.073151.2920 ± 0.75690
C40.0198 ± 0.00976NA ± NA
C50.0140 ± 0.00760NA ± NA
C70.0137 ± 0.00484NA ± NA
C80.0441 ± 0.021470.0145 ± 0.00648
C13NA ± NANA ± NA
PrimaryPlasma Concentration of Monomethylauristatin E (MMAE) and Its Metabolites at Cycle 1, 336 Hour Postdose

Metabolites of MMAE includes C4, C5, C7, C8 and C13. The LLQ for all the observations was 0.01 ng/mL.

Time frame:
Cycle 1: 336 hour postdose
Reported as:
Geometric mean · ng/mL
Plasma Concentration of Monomethylauristatin E (MMAE) and Its Metabolites at Cycle 1, 336 Hour Postdose
ng/mLBrentuximab VedotinBrentuximab Vedotin + Rifampicin
MMAE0.3130 ± 0.157430.2723 ± 0.16544
C4NA ± NANA ± NA
C5NA ± NANA ± NA
C7NA ± NANA ± NA
C80.0127 ± 0.00672NA ± NA
C13NA ± NANA ± NA
PrimaryPlasma Concentration of Monomethylauristatin E (MMAE) and Its Metabolites at Cycle 3, 336 Hour Postdose

Metabolites of MMAE includes C4, C5, C7, C8 and C13. The LLQ for all the observations was 0.01 ng/mL.

Time frame:
Cycle 3: 336 hour postdose
Reported as:
Geometric mean · ng/mL
Plasma Concentration of Monomethylauristatin E (MMAE) and Its Metabolites at Cycle 3, 336 Hour Postdose
ng/mLBrentuximab VedotinBrentuximab Vedotin + Rifampicin
MMAE0.4258 ± 0.305650.2578 ± 0.10847
C4NA ± NANA ± NA
C5NA ± NANA ± NA
C7NA ± NANA ± NA
C80.0168 ± 0.01011NA ± NA
C13NA ± NANA ± NA
PrimaryPlasma Concentration of Monomethylauristatin E (MMAE) and Its Metabolites at Cycle 3, 480 Hour Postdose

Metabolites of MMAE includes C4, C5, C7, C8 and C13. The LLQ for all the observations was 0.01 ng/mL.

Time frame:
Cycle 3: 480 hour postdose
Reported as:
Geometric mean · ng/mL
Plasma Concentration of Monomethylauristatin E (MMAE) and Its Metabolites at Cycle 3, 480 Hour Postdose
ng/mLBrentuximab VedotinBrentuximab Vedotin + Rifampicin
MMAE0.1189 ± 0.158080.0941 ± 0.03974
C4NA ± NANA ± NA
C5NA ± NANA ± NA
C7NA ± NANA ± NA
C80.0114 ± 0.00431NA ± NA
C13NA ± NANA ± NA
SecondaryNumber of Participants Reporting One or More Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)

An Adverse Event (AE) is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (example, a clinically significant abnormal laboratory finding), symptom, or disease temporally associated with the use of a drug, whether or not it is considered related to the drug. A treatment-emergent adverse event (TEAE) is defined as an adverse event with an onset that occurs after receiving study drug. A serious adverse event (SAE) is an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; or congenital anomaly; or a medically important event. AEs included both SAE and non-SAE.

Time frame:
Baseline up to 30 days after last dose of study drug (30 days after Cycle 16)
Reported as:
Number · participants
Number of Participants Reporting One or More Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)
participantsBrentuximab VedotinBrentuximab Vedotin + Rifampicin
AEs99
SAEs40
SecondaryNumber of Participants With Anti-therapeutic Antibodies (ATA) to Brentuximab Vedotin

Participants with positive ATA at both Cycle 1 and 3, negative ATA at both Cycle 1 and 3, and transient positive (positive at one time point, but negative at the other) ATA for brentuximab vedotin were reported.

Time frame:
Day 1 of Cycle 1 and 3
Reported as:
Number · participants
Number of Participants With Anti-therapeutic Antibodies (ATA) to Brentuximab Vedotin
participantsBrentuximab VedotinBrentuximab Vedotin + Rifampicin
Negative in both Cycle 1 and 357
Positive in both Cycle 1 and 310
Transient Positive22
SecondaryNumber of Participants With Markedly Abnormal Laboratory Values

The number of participants with any markedly abnormal standard safety laboratory values collected throughout study.

Time frame:
Baseline up to 30 days after last dose of study drug (30 Days after Cycle 16)
Reported as:
Number · participants
Number of Participants With Markedly Abnormal Laboratory Values
participantsBrentuximab VedotinBrentuximab Vedotin + Rifampicin
Number of Participants With Markedly Abnormal Laboratory Values55
PrimaryAmount of Monomethylauristatin E (MMAE) and Its Metabolites Excreted in Urine at Cycle 1, Predose

Metabolites of MMAE includes C4, C5, C7, C8 and C13. Amount of MMAE and its metabolites in urine were determined by multiplying the volume of urine obtained and the concentration of MMAE and its metabolites present in it, respectively. The LLQ for determining the concentration was 0.01 ng/mL.

Time frame:
Cycle 1: Predose
Reported as:
Geometric mean · ng
Amount of Monomethylauristatin E (MMAE) and Its Metabolites Excreted in Urine at Cycle 1, Predose
ngBrentuximab VedotinBrentuximab Vedotin + Rifampicin
MMAENA ± NA7.8900 ± 2.63000
C4NA ± NANA ± NA
C5NA ± NANA ± NA
C7NA ± NANA ± NA
C8NA ± NA0.0712 ± 0.02373
C13NA ± NANA ± NA
PrimaryAmount of Monomethylauristatin E (MMAE) and Its Metabolites Excreted in Urine at Cycle 1, 0-24 Hours Postdose

Metabolites of MMAE includes C4, C5, C7, C8 and C13. Amount of MMAE and its metabolites in urine were determined by multiplying the volume of urine obtained and the concentration of MMAE and its metabolites present in it, respectively. The LLQ for determining the concentration was 0.01 ng/mL.

Time frame:
Cycle 1: 0-24 hours postdose
Reported as:
Geometric mean · ng
Amount of Monomethylauristatin E (MMAE) and Its Metabolites Excreted in Urine at Cycle 1, 0-24 Hours Postdose
ngBrentuximab VedotinBrentuximab Vedotin + Rifampicin
MMAE12.5668 ± 5.3137412.5020 ± 6.85958
C40.0878 ± 0.132230.0521 ± 0.02335
C50.0883 ± 0.101350.0254 ± 0.00847
C7NA ± NANA ± NA
C80.5967 ± 0.562210.1047 ± 0.07785
C130.0786 ± 0.114600.0456 ± 0.03714
PrimaryAmount of Monomethylauristatin E (MMAE) and Its Metabolites Excreted in Urine at Cycle 1, 24-48 Hours Postdose

Metabolites of MMAE includes C4, C5, C7, C8 and C13. Amount of MMAE and its metabolites in urine were determined by multiplying the volume of urine obtained and the concentration of MMAE and its metabolites present in it, respectively. The LLQ for determining the concentration was 0.01 ng/mL.

Time frame:
Cycle 1: 24-48 hours postdose
Reported as:
Geometric mean · ng
Amount of Monomethylauristatin E (MMAE) and Its Metabolites Excreted in Urine at Cycle 1, 24-48 Hours Postdose
ngBrentuximab VedotinBrentuximab Vedotin + Rifampicin
MMAE12.6225 ± 6.9373511.7995 ± 6.20286
C40.0690 ± 0.109350.0392 ± 0.03010
C50.0863 ± 0.091380.0277 ± 0.01700
C7NA ± NANA ± NA
C80.7275 ± 0.597160.1568 ± 0.08381
C130.0722 ± 0.074820.0405 ± 0.03473
PrimaryAmount of Monomethylauristatin E (MMAE) and Its Metabolites Excreted in Urine at Cycle 1, 48-72 Hours Postdose

Metabolites of MMAE includes C4, C5, C7, C8 and C13. Amount of MMAE and its metabolites in urine were determined by multiplying the volume of urine obtained and the concentration of MMAE and its metabolites present in it, respectively. The LLQ for determining the concentration was 0.01 ng/mL.

Time frame:
Cycle 1: 48-72 hours postdose
Reported as:
Geometric mean · ng
Amount of Monomethylauristatin E (MMAE) and Its Metabolites Excreted in Urine at Cycle 1, 48-72 Hours Postdose
ngBrentuximab VedotinBrentuximab Vedotin + Rifampicin
MMAE12.4089 ± 4.4992211.6600 ± 5.45329
C40.0812 ± 0.150060.0419 ± 0.02694
C50.0867 ± 0.108410.0322 ± 0.01859
C7NA ± NANA ± NA
C80.7973 ± 0.382260.1189 ± 0.08494
C130.0786 ± 0.056720.0382 ± 0.02718
PrimaryAmount of Monomethylauristatin E (MMAE) and Its Metabolites Excreted in Urine at Cycle 1, 72-96 Hours Postdose

Metabolites of MMAE includes C4, C5, C7, C8 and C13. Amount of MMAE and its metabolites in urine were determined by multiplying the volume of urine obtained and the concentration of MMAE and its metabolites present in it, respectively. The LLQ for determining the concentration was 0.01 ng/mL.

Time frame:
Cycle 1: 72-96 hours postdose
Reported as:
Geometric mean · ng
Amount of Monomethylauristatin E (MMAE) and Its Metabolites Excreted in Urine at Cycle 1, 72-96 Hours Postdose
ngBrentuximab VedotinBrentuximab Vedotin + Rifampicin
MMAE10.7766 ± 8.1485812.8426 ± 5.93538
C40.0867 ± 0.164490.0427 ± 0.02848
C50.0882 ± 0.112020.0394 ± 0.02131
C7NA ± NANA ± NA
C80.7480 ± 0.612190.1247 ± 0.08379
C130.0754 ± 0.068200.0415 ± 0.02723
PrimaryAmount of Monomethylauristatin E (MMAE) and Its Metabolites Excreted in Urine at Cycle 1, 96-120 Hours Postdose

Metabolites of MMAE includes C4, C5, C7, C8 and C13. Amount of MMAE and its metabolites in urine were determined by multiplying the volume of urine obtained and the concentration of MMAE and its metabolites present in it, respectively. The LLQ for determining the concentration was 0.01 ng/mL.

Time frame:
Cycle 1: 96-120 hours postdose
Reported as:
Geometric mean · ng
Amount of Monomethylauristatin E (MMAE) and Its Metabolites Excreted in Urine at Cycle 1, 96-120 Hours Postdose
ngBrentuximab VedotinBrentuximab Vedotin + Rifampicin
MMAE10.8018 ± 12.034319.5626 ± 7.26020
C40.0885 ± 0.118110.0414 ± 0.03529
C50.1053 ± 0.106390.0406 ± 0.02753
C7NA ± NANA ± NA
C80.7360 ± 1.024170.1034 ± 0.10563
C130.0630 ± 0.081550.0380 ± 0.03436
PrimaryAmount of Monomethylauristatin E (MMAE) and Its Metabolites Excreted in Urine at Cycle 1, 120-144 Hours Postdose

Metabolites of MMAE includes C4, C5, C7, C8 and C13. Amount of MMAE and its metabolites in urine were determined by multiplying the volume of urine obtained and the concentration of MMAE and its metabolites present in it, respectively. The LLQ for determining the concentration was 0.01 ng/mL.

Time frame:
Cycle 1: 120-144 hours postdose
Reported as:
Geometric mean · ng
Amount of Monomethylauristatin E (MMAE) and Its Metabolites Excreted in Urine at Cycle 1, 120-144 Hours Postdose
ngBrentuximab VedotinBrentuximab Vedotin + Rifampicin
MMAE6.7161 ± 6.139977.9830 ± 4.33309
C40.0730 ± 0.083870.0335 ± 0.02037
C50.0836 ± 0.073770.0301 ± 0.01767
C7NA ± NANA ± NA
C80.4477 ± 0.560470.0910 ± 0.06044
C130.0551 ± 0.051070.0345 ± 0.01738
PrimaryAmount of Monomethylauristatin E (MMAE) and Its Metabolites Excreted in Urine at Cycle 1, 144-168 Hours Postdose

Metabolites of MMAE includes C4, C5, C7, C8 and C13. Amount of MMAE and its metabolites in urine were determined by multiplying the volume of urine obtained and the concentration of MMAE and its metabolites present in it, respectively. The LLQ for determining the concentration was 0.01 ng/mL.

Time frame:
Cycle 1: 144-168 hours postdose
Reported as:
Geometric mean · ng
Amount of Monomethylauristatin E (MMAE) and Its Metabolites Excreted in Urine at Cycle 1, 144-168 Hours Postdose
ngBrentuximab VedotinBrentuximab Vedotin + Rifampicin
MMAE5.5693 ± 3.509455.8025 ± 3.45889
C40.0579 ± 0.068070.0448 ± 0.02158
C50.0747 ± 0.050780.0287 ± 0.01527
C7NA ± NANA ± NA
C80.3916 ± 0.344910.0706 ± 0.03027
C130.0438 ± 0.031460.0363 ± 0.01283
PrimaryAmount of Monomethylauristatin E (MMAE) and Its Metabolites Excreted in Urine at Cycle 1, 336-360 Hours Postdose

Metabolites of MMAE includes C4, C5, C7, C8 and C13. Amount of MMAE and its metabolites in urine were determined by multiplying the volume of urine obtained and the concentration of MMAE and its metabolites present in it, respectively. The LLQ for determining the concentration was 0.01 ng/mL.

Time frame:
Cycle 1: 336-360 hours postdose
Reported as:
Geometric mean · ng
Amount of Monomethylauristatin E (MMAE) and Its Metabolites Excreted in Urine at Cycle 1, 336-360 Hours Postdose
ngBrentuximab VedotinBrentuximab Vedotin + Rifampicin
MMAE1.0727 ± 0.552331.3326 ± 0.80959
C40.0459 ± 0.01530NA ± NA
C50.0289 ± 0.00963NA ± NA
C7NA ± NANA ± NA
C80.0751 ± 0.045050.0401 ± 0.02242
C13NA ± NANA ± NA
PrimaryAmount of Monomethylauristatin E (MMAE) and Its Metabolites Excreted in Urine at Cycle 1, 480-504 Hours Postdose

Metabolites of MMAE includes C4, C5, C7, C8 and C13. Amount of MMAE and its metabolites in urine were determined by multiplying the volume of urine obtained and the concentration of MMAE and its metabolites present in it, respectively. The LLQ for determining the concentration was 0.01 ng/mL.

Time frame:
Cycle 1: 480-504 hours postdose
Reported as:
Geometric mean · ng
Amount of Monomethylauristatin E (MMAE) and Its Metabolites Excreted in Urine at Cycle 1, 480-504 Hours Postdose
ngBrentuximab VedotinBrentuximab Vedotin + Rifampicin
MMAE0.4420 ± 0.307450.3505 ± 0.14592
C4NA ± NANA ± NA
C5NA ± NANA ± NA
C7NA ± NANA ± NA
C80.0578 ± 0.03314NA ± NA
C13NA ± NANA ± NA
PrimaryAmount of Monomethylauristatin E (MMAE) and Its Metabolites Excreted in Urine at Cycle 3, Predose

Metabolites of MMAE includes C4, C5, C7, C8 and C13. Amount of MMAE and its metabolites in urine were determined by multiplying the volume of urine obtained and the concentration of MMAE and its metabolites present in it, respectively. The LLQ for determining the concentration was 0.01 ng/mL.

Time frame:
Cycle 3: Predose
Reported as:
Geometric mean · ng
Amount of Monomethylauristatin E (MMAE) and Its Metabolites Excreted in Urine at Cycle 3, Predose
ngBrentuximab VedotinBrentuximab Vedotin + Rifampicin
MMAE0.3171 ± 0.335480.4227 ± 0.17918
C4NA ± NANA ± NA
C5NA ± NANA ± NA
C7NA ± NANA ± NA
C80.0392 ± 0.02985NA ± NA
C13NA ± NANA ± NA
PrimaryAmount of Monomethylauristatin E (MMAE) and Its Metabolites Excreted in Urine at Cycle 3, 0-24 Hours Postdose

Metabolites of MMAE includes C4, C5, C7, C8 and C13. Amount of MMAE and its metabolites in urine were determined by multiplying the volume of urine obtained and the concentration of MMAE and its metabolites present in it, respectively. The LLQ for determining the concentration was 0.01 ng/mL.

Time frame:
Cycle 3: 0-24 hours postdose
Reported as:
Geometric mean · ng
Amount of Monomethylauristatin E (MMAE) and Its Metabolites Excreted in Urine at Cycle 3, 0-24 Hours Postdose
ngBrentuximab VedotinBrentuximab Vedotin + Rifampicin
MMAE10.7174 ± 15.3591212.4438 ± 8.86144
C40.0454 ± 0.076440.0451 ± 0.02977
C50.0509 ± 0.046230.0301 ± 0.01847
C7NA ± NANA ± NA
C80.4657 ± 0.413520.1285 ± 0.17930
C130.0516 ± 0.070450.0676 ± 0.05022
PrimaryAmount of Monomethylauristatin E (MMAE) and Its Metabolites Excreted in Urine at Cycle 3, 24-48 Hours Postdose

Metabolites of MMAE includes C4, C5, C7, C8 and C13. Amount of MMAE and its metabolites in urine were determined by multiplying the volume of urine obtained and the concentration of MMAE and its metabolites present in it, respectively. The LLQ for determining the concentration was 0.01 ng/mL.

Time frame:
Cycle 3: 24-48 hours postdose
Reported as:
Geometric mean · ng
Amount of Monomethylauristatin E (MMAE) and Its Metabolites Excreted in Urine at Cycle 3, 24-48 Hours Postdose
ngBrentuximab VedotinBrentuximab Vedotin + Rifampicin
MMAE11.1360 ± 6.7369313.2483 ± 4.79482
C40.0604 ± 0.050490.0413 ± 0.03095
C50.0808 ± 0.068380.0311 ± 0.02021
C7NA ± NANA ± NA
C80.5750 ± 0.581960.1600 ± 0.11946
C130.0637 ± 0.051020.0507 ± 0.03607
PrimaryAmount of Monomethylauristatin E (MMAE) and Its Metabolites Excreted in Urine at Cycle 3, 48-72 Hours Postdose

Metabolites of MMAE includes C4, C5, C7, C8 and C13. Amount of MMAE and its metabolites in urine were determined by multiplying the volume of urine obtained and the concentration of MMAE and its metabolites present in it, respectively. The LLQ for determining the concentration was 0.01 ng/mL.

Time frame:
Cycle 3: 48-72 hours postdose
Reported as:
Geometric mean · ng
Amount of Monomethylauristatin E (MMAE) and Its Metabolites Excreted in Urine at Cycle 3, 48-72 Hours Postdose
ngBrentuximab VedotinBrentuximab Vedotin + Rifampicin
MMAE12.7267 ± 8.9699113.8072 ± 8.63973
C40.0620 ± 0.062220.0524 ± 0.04691
C50.0746 ± 0.092370.0406 ± 0.03034
C7NA ± NANA ± NA
C80.6950 ± 0.835880.1598 ± 0.14846
C130.0632 ± 0.064800.0746 ± 0.05134
PrimaryAmount of Monomethylauristatin E (MMAE) and Its Metabolites Excreted in Urine at Cycle 3, 72-96 Hours Postdose

Metabolites of MMAE includes C4, C5, C7, C8 and C13. Amount of MMAE and its metabolites in urine were determined by multiplying the volume of urine obtained and the concentration of MMAE and its metabolites present in it, respectively. The LLQ for determining the concentration was 0.01 ng/mL.

Time frame:
Cycle 3: 72-96 hours postdose
Reported as:
Geometric mean · ng
Amount of Monomethylauristatin E (MMAE) and Its Metabolites Excreted in Urine at Cycle 3, 72-96 Hours Postdose
ngBrentuximab VedotinBrentuximab Vedotin + Rifampicin
MMAE11.2527 ± 8.6557412.2263 ± 6.09003
C40.0702 ± 0.070790.0611 ± 0.05055
C50.0937 ± 0.107570.0437 ± 0.03084
C7NA ± NANA ± NA
C80.5276 ± 0.955070.1510 ± 0.11532
C130.0573 ± 0.077340.0564 ± 0.03759
PrimaryAmount of Monomethylauristatin E (MMAE) and Its Metabolites Excreted in Urine at Cycle 3, 96-120 Hours Postdose

Metabolites of MMAE includes C4, C5, C7, C8 and C13. Amount of MMAE and its metabolites in urine were determined by multiplying the volume of urine obtained and the concentration of MMAE and its metabolites present in it, respectively. The LLQ for determining the concentration was 0.01 ng/mL.

Time frame:
Cycle 3: 96-120 hours postdose
Reported as:
Geometric mean · ng
Amount of Monomethylauristatin E (MMAE) and Its Metabolites Excreted in Urine at Cycle 3, 96-120 Hours Postdose
ngBrentuximab VedotinBrentuximab Vedotin + Rifampicin
MMAE8.3817 ± 7.782798.1426 ± 7.29530
C40.0710 ± 0.059120.0512 ± 0.04137
C50.0916 ± 0.088930.0435 ± 0.02885
C7NA ± NANA ± NA
C80.5198 ± 0.796340.1088 ± 0.09569
C130.0607 ± 0.068380.0524 ± 0.03619
PrimaryAmount of Monomethylauristatin E (MMAE) and Its Metabolites Excreted in Urine at Cycle 3, 120-144 Hours Postdose

Metabolites of MMAE includes C4, C5, C7, C8 and C13. Amount of MMAE and its metabolites in urine were determined by multiplying the volume of urine obtained and the concentration of MMAE and its metabolites present in it, respectively. The LLQ for determining the concentration was 0.01 ng/mL.

Time frame:
Cycle 3: 120-144 hours postdose
Reported as:
Geometric mean · ng
Amount of Monomethylauristatin E (MMAE) and Its Metabolites Excreted in Urine at Cycle 3, 120-144 Hours Postdose
ngBrentuximab VedotinBrentuximab Vedotin + Rifampicin
MMAE7.3500 ± 3.784277.5871 ± 4.66863
C40.0461 ± 0.036660.0520 ± 0.03870
C50.0657 ± 0.048110.0342 ± 0.02508
C7NA ± NANA ± NA
C80.4700 ± 0.371310.0869 ± 0.07672
C130.0386 ± 0.032120.0429 ± 0.02820
PrimaryAmount of Monomethylauristatin E (MMAE) and Its Metabolites Excreted in Urine at Cycle 3, 144-168 Hours Postdose

Metabolites of MMAE includes C4, C5, C7, C8 and C13. Amount of MMAE and its metabolites in urine were determined by multiplying the volume of urine obtained and the concentration of MMAE and its metabolites present in it, respectively. The LLQ for determining the concentration was 0.01 ng/mL.

Time frame:
Cycle 3: 144-168 hours postdose
Reported as:
Geometric mean · ng
Amount of Monomethylauristatin E (MMAE) and Its Metabolites Excreted in Urine at Cycle 3, 144-168 Hours Postdose
ngBrentuximab VedotinBrentuximab Vedotin + Rifampicin
MMAE6.1125 ± 3.832074.6823 ± 2.80767
C40.0538 ± 0.042520.0562 ± 0.02674
C50.0662 ± 0.061100.0308 ± 0.01718
C7NA ± NANA ± NA
C80.3485 ± 0.458980.0651 ± 0.03984
C130.0402 ± 0.041170.0481 ± 0.01603
PrimaryAmount of Monomethylauristatin E (MMAE) and Its Metabolites Excreted in Urine at Cycle 3, 336-360 Hours Postdose

Metabolites of MMAE includes C4, C5, C7, C8 and C13. Amount of MMAE and its metabolites in urine were determined by multiplying the volume of urine obtained and the concentration of MMAE and its metabolites present in it, respectively. The LLQ for determining the concentration was 0.01 ng/mL.

Time frame:
Cycle 3: 336-360 hours postdose
Reported as:
Geometric mean · ng
Amount of Monomethylauristatin E (MMAE) and Its Metabolites Excreted in Urine at Cycle 3, 336-360 Hours Postdose
ngBrentuximab VedotinBrentuximab Vedotin + Rifampicin
MMAE1.2811 ± 1.550680.8271 ± 0.43597
C40.0377 ± 0.01812NA ± NA
C50.0347 ± 0.02457NA ± NA
C7NA ± NANA ± NA
C80.0734 ± 0.109580.0277 ± 0.01306
C130.0227 ± 0.00757NA ± NA
SecondaryNumber of Participants With Clinically Significant Change From Baseline in Vital Signs

Vital signs included body temperature, body weight, blood pressure and heart rate.

Time frame:
Baseline up to 30 days after last dose of study drug (30 Days after Cycle 16)
Reported as:
Number · participants
Number of Participants With Clinically Significant Change From Baseline in Vital Signs
participantsBrentuximab VedotinBrentuximab Vedotin + Rifampicin
Number of Participants With Clinically Significant Change From Baseline in Vital Signs12
PrimaryAmount of Monomethylauristatin E (MMAE) and Its Metabolites Excreted in Urine at Cycle 3, 480-504 Hours Postdose

Metabolites of MMAE includes C4, C5, C7, C8 and C13. Amount of MMAE and its metabolites in urine were determined by multiplying the volume of urine obtained and the concentration of MMAE and its metabolites present in it, respectively. The LLQ for determining the concentration was 0.01 ng/mL.

Time frame:
Cycle 3: 480-504 hours postdose
Reported as:
Geometric mean · ng
Amount of Monomethylauristatin E (MMAE) and Its Metabolites Excreted in Urine at Cycle 3, 480-504 Hours Postdose
ngBrentuximab VedotinBrentuximab Vedotin + Rifampicin
MMAE0.4660 ± 0.417130.3334 ± 0.25074
C40.0248 ± 0.00827NA ± NA
C50.0377 ± 0.01257NA ± NA
C7NA ± NANA ± NA
C80.0620 ± 0.049670.0221 ± 0.00737
C13NA ± NANA ± NA

Adverse events

Collected over Treatment-emergent adverse events are adverse events that started after the first dose of study drug and no more than 30 days after the last dose of study drug (30 days after Cycle 16).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Brentuximab Vedotin—4/10 (40%)9/10 (90%)
Brentuximab Vedotin + Rifampicin—0/10 (0%)9/10 (90%)
Most frequent serious events
Most frequent serious events
EventBrentuximab VedotinBrentuximab Vedotin + Rifampicin
Respiratory failureRespiratory, thoracic and mediastinal disorders2/100/10
Thrombosis in deviceGeneral disorders1/100/10
PyrexiaGeneral disorders1/100/10
Staphylococcal infectionInfections and infestations1/100/10
Pulmonary tuberculosisInfections and infestations1/100/10
Pulmonary embolismRespiratory, thoracic and mediastinal disorders1/100/10
Pneumocystis jirovecii pneumoniaInfections and infestations1/100/10
NeuralgiaNervous system disorders1/100/10
Most frequent other events
Showing 10 of 63
Most frequent other events
EventBrentuximab VedotinBrentuximab Vedotin + Rifampicin
PruritusSkin and subcutaneous tissue disorders3/103/10
NeutropeniaBlood and lymphatic system disorders3/102/10
AnaemiaBlood and lymphatic system disorders2/102/10
DiarrhoeaGastrointestinal disorders1/102/10
DyspnoeaRespiratory, thoracic and mediastinal disorders1/102/10
EosinophiliaBlood and lymphatic system disorders1/102/10
HypokalaemiaMetabolism and nutrition disorders2/101/10
HypomagnesaemiaMetabolism and nutrition disorders2/101/10
Peripheral sensory neuropathyNervous system disorders1/102/10
PyrexiaGeneral disorders1/102/10

Baseline characteristics

Safety population included all participants who received at least 1 dose of study drug.

Age, Continuous
Age, Continuous(years)Brentuximab VedotinBrentuximab Vedotin + RifampicinTotal
Mean42.3 ± 12.1540.1 ± 9.1341.2 ± 10.52
Sex: Female, Male
Sex: Female, Male(Participants)Brentuximab VedotinBrentuximab Vedotin + RifampicinTotal
Female369
Male7411
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)Brentuximab VedotinBrentuximab Vedotin + RifampicinTotal
White101020
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)Brentuximab VedotinBrentuximab Vedotin + RifampicinTotal
Not Hispanic or Latino101020
Region of Enrollment
Region of Enrollment(participants)Brentuximab VedotinBrentuximab Vedotin + RifampicinTotal
Spain459
Belgium213
Lithuania448
Weight
Weight(kilogram (kg))Brentuximab VedotinBrentuximab Vedotin + RifampicinTotal
Mean71.11 ± 17.05676.84 ± 24.21373.98 ± 20.595
Height
Height(centimeter (cm))Brentuximab VedotinBrentuximab Vedotin + RifampicinTotal
Mean169.9 ± 3.80169.7 ± 6.45169.8 ± 5.15
Eastern Cooperative Oncology Group (ECOG) Performance Status
Eastern Cooperative Oncology Group (ECOG) Performance Status(participants)Brentuximab VedotinBrentuximab Vedotin + RifampicinTotal
0369
16410
2101

3 further baseline measures are reported on the registry.

08

Study locations

6 sites
  • Brussels, Belgium
  • Gent, Belgium
  • Vilnius, Lithuania
  • Barcelona, Spain
  • Madrid, Spain
  • Salamanca, Spain
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2013, a primary completion of Oct 2014 and a completion of Jun 2015. It does not say whether these dates are actual or estimated.

Results were first posted in Feb 2016, 1 year 4 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 23, 2013
First posted
Sep 25, 2013
Start
Nov 2013
Primary completionActual
Oct 2014
CompletionActual
Jun 2015
Results first posted
Feb 9, 2016
Last update
May 11, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 11, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01950364
Responsible party
Sponsor
First posted
Sep 25, 2013
Start date
Nov 2013
Primary completion
Oct 2014
Completion
Jun 2015
Results posted
Feb 9, 2016
Last update
May 11, 2016

Study contacts

Medical Monitor
study director · Millennium Pharmaceuticals, Inc.

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Brentuximab Vedotin · Rifampin

Start the discussion